Bio-Techne Q2 organic revenue down 2% to $272.6M; GAAP EPS $0.17 vs $0.31 YoY; declares $0.08 dividend

BIO-TECHNE Corp

2024-Q2 EPS reported $0.49 revenue$549,533,000

Q2 organic revenue declined 2% to $272.6M; reported revenue flat vs prior year.
GAAP EPS $0.17 vs $0.31 YoY; adjusted EPS $0.40 vs $0.47.
Cash flow from operations $142.5M, up 18% YoY.
Board declared $0.08 per share quarterly dividend, payable Feb 26, 2024.
Dr. Matthew F. McManus appointed President of Diagnostics and Genomics segment.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIO-TECHNE Corp reported financial results for second quarter ended December 31, 2023.

Period: second quarter ended December 31, 2023
Result: reported results

Exact text from the filing

A copy of the press release issued by Bio-Techne Corporation on February 1, 2024, describing the results of operations for the quarter ended December 31, 2023, and its financial condition as of December 31, 2023 is attached hereto as Exhibit 99.1.

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

BIO-TECHNE Corp filing history →

Source: SEC EDGAR

accession 0001558370-24-000683

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.